Summary:
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Eczema/Atopic Dermatitis
Treatment for patients with moderate to severe eczema.
Criteria:- Male or female subjects aged ≥ 12 years at the screening visit.
- Chronic eczema that has been documented for at least 2 years
- Involves more than 10% of body surface area
Qualified Participants May Receive:
- Payment for participating
- Travel expenses reimbursed
- Treatment at no cost